Muutke küpsiste eelistusi

Plasma Cell Dyscrasias 2016 ed. [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 361 pages, kõrgus x laius: 235x155 mm, kaal: 6742 g, 7 Illustrations, color; 2 Illustrations, black and white; VI, 361 p. 9 illus., 7 illus. in color., 1 Hardback
  • Sari: Cancer Treatment and Research 169
  • Ilmumisaeg: 11-Oct-2016
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3319403184
  • ISBN-13: 9783319403182
Teised raamatud teemal:
  • Kõva köide
  • Hind: 141,35 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 166,29 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 361 pages, kõrgus x laius: 235x155 mm, kaal: 6742 g, 7 Illustrations, color; 2 Illustrations, black and white; VI, 361 p. 9 illus., 7 illus. in color., 1 Hardback
  • Sari: Cancer Treatment and Research 169
  • Ilmumisaeg: 11-Oct-2016
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3319403184
  • ISBN-13: 9783319403182
Teised raamatud teemal:
This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström"s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.

MGUS and smoldering myeloma.- Multiple Myeloma.- Primary amyloidosis, systemic light chain and heavy chain diseases plasmacytoma.- Waldenstrom"s Macroglobulinemia.
Part I Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma
MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology
3(12)
Maria-Victoria Mateos
Ola Landgren
Part II Multiple Myeloma
Vision Statement for Multiple Myeloma: Future Directions
15(8)
Kenneth C. Anderson
Genomic Aberrations in Multiple Myeloma
23(12)
Salomon Manier
Karma Salem
Siobhan V. Glavey
Aldo M. Roccaro
Irene M. Ghobrial
Epigenetics in Multiple Myeloma
35(16)
Siobhan V. Glavey
Salomon Manier
Antonio Sacco
Karma Salem
Yawara Kawano
Juliette Bouyssou
Irene M. Ghobrial
Aldo M. Roccaro
Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch
51(12)
Domenico Ribatti
Angelo Vacca
Targeting the Bone Marrow Microenvironment
63(40)
Michele Moschetta
Yawara Kawano
Klaus Podar
Multiple Myeloma Minimal Residual Disease
103(20)
Bruno Paiva
Ramon Garcia-Sanz
Jesus F. San Miguel
Treatment of Newly Diagnosed Elderly Multiple Myeloma
123(22)
Guillemette Fouquet
Francesca Gay
Eileen Boyle
Sara Bringhen
Alessandra Larocca
Thierry Facon
Xavier Leleu
Antonio Palumbo
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
145(24)
Jacob Laubach
Shaji Kumar
Treatment of Relapsed/Refractory Multiple Myeloma
169(26)
Paola Neri
Nizar J. Bahlis
Claudia Paba-Prada
Paul Richardson
Treatment of MM: Upcoming Novel Therapies
195(12)
Sagar Lonial
Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma
207(20)
Susan J. Lee
Ivan Borrello
Transplantation for Multiple Myeloma
227(24)
Yogesh S. Jethava
Frits van Rhee
Bone Disease in Multiple Myeloma
251(22)
Homare Eda
Loredana Santo
G. David Roodman
Noopur Raje
Part III Primary Amyloidosis, Systemic Light Chain and Heavy Chain Diseases, Plasmacytoma
Immunoglobulin Light Chain Systemic Amyloidosis
273(48)
Angela Dispenzieri
Giampaolo Merlini
Part IV Waldenstrom's Macroglobulinemia
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment
321
Prashant Kapoor
Stephen M. Ansell
Esteban Braggio